BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Slevin SM, Egan LJ. New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:2909-2920. [PMID: 26348448 DOI: 10.1097/mib.0000000000000533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Deora A, Hegde S, Lee J, Choi CH, Chang Q, Lee C, Eaton L, Tang H, Wang D, Lee D, Michalak M, Tomlinson M, Tao Q, Gaur N, Harvey B, McLoughlin S, Labkovsky B, Ghayur T. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs 2017;9:680-95. [PMID: 28323513 DOI: 10.1080/19420862.2017.1304869] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
2 Chang S, Hanauer S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2017;15:53-70. [PMID: 28164249 DOI: 10.1007/s11938-017-0122-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016; 22(42): 9300-9313 [PMID: 27895418 DOI: 10.3748/wjg.v22.i42.9300] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 83] [Article Influence: 15.2] [Reference Citation Analysis]
4 Kunchok A, Aksamit AJ Jr, Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, Weinshenker BG, McKeon A. Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurol 2020;77:937-46. [PMID: 32421186 DOI: 10.1001/jamaneurol.2020.1162] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
5 Tekari A, Marazza A, Crump K, Bermudez-Lekerika P, Gantenbein B. Inhibition of the extracellular signal-regulated kinase pathway reduces the inflammatory component in nucleus pulposus cells. J Orthop Res 2022. [PMID: 35106811 DOI: 10.1002/jor.25273] [Reference Citation Analysis]
6 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
7 Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, Nielsen OH. Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease. Medicine (Baltimore) 2016;95:e3417. [PMID: 27100432 DOI: 10.1097/MD.0000000000003417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
8 Bufan B, Jančić I, Stojić-vukanić Z. Inhibitors of tumor necrosis factor-a and mechanisms of their action. Arhiv za farmaciju 2020;70:109-29. [DOI: 10.5937/arhfarm2003109b] [Reference Citation Analysis]
9 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
10 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Lauro R, Mannino F, Irrera N, Squadrito F, Altavilla D, Squadrito G, Pallio G, Bitto A. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021;9:1748. [PMID: 34944563 DOI: 10.3390/biomedicines9121748] [Reference Citation Analysis]
12 Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut Microbiome-Current State of Art. Int J Mol Sci 2021;22:4529. [PMID: 33926088 DOI: 10.3390/ijms22094529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]